THYQUIDITY Drug Patent Profile

When do Thyquidity patents expire, and what generic alternatives are available?

Thyquidity is a drug marketed by Stevens J and is included in one NDA. There is one patent protecting this drug and one Paragraph IV challenge.

This drug has eleven patent family members in eleven countries.

The generic ingredient in THYQUIDITY is levothyroxine sodium. There are ten drug master file entries for this compound. Fifty-three suppliers are listed for this compound. Additional details are available on the levothyroxine sodium profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Thyquidity

A generic version of THYQUIDITY was approved as levothyroxine sodium by MYLAN on June 5^th, 2002.

Summary for THYQUIDITY

International Patents:	11
US Patents:	1
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	54
Patent Applications:	2,521
Drug Prices:	Drug price information for THYQUIDITY
What excipients (inactive ingredients) are in THYQUIDITY?	THYQUIDITY excipients list
DailyMed Link:	THYQUIDITY at DailyMed

See drug prices for THYQUIDITY

Pharmacology for THYQUIDITY

Drug Class

l-Thyroxine

Paragraph IV (Patent) Challenges for THYQUIDITY

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
THYQUIDITY	Oral Solution	levothyroxine sodium	100 mcg/5 mL	214047	1	2022-12-28

US Patents and Regulatory Information for THYQUIDITY

THYQUIDITY is protected by one US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Stevens J	THYQUIDITY	levothyroxine sodium	SOLUTION;ORAL	214047-001	Nov 30, 2020		RX	Yes	Yes			Y

International Patents for THYQUIDITY

See the table below for patents covering THYQUIDITY around the world.

Country	Patent Number	Title	Estimated Expiration
Cyprus	1117151
Poland	2683361
Serbia	54524	POSTUPAK PRIPREME RASTVORA LEVOTIROKSINA (METHOD FOR THE PREPARATON OF A LEVOTHYROXINE SOLUTION)
World Intellectual Property Organization (WIPO)	2012120338

Market Dynamics and Financial Trajectory for the Pharmaceutical Drug: THYQUIDITY

Last updated: July 29, 2025

Introduction

THYQUIDITY, a novel pharmaceutical agent, is positioned within the rapidly evolving landscape of thyroid hormone replacement therapies. As a synthetic, potentially more effective, and safer alternative to existing treatments, understanding its market dynamics and financial trajectory is critical for stakeholders, including investors, healthcare providers, and policymakers. This analysis synthesizes current market trends, competitive landscape, regulatory outlook, and projected financial pathways for THYQUIDITY.

Market Overview

Thyroid Disorder Therapeutics Landscape

Thyroid disorders, notably hypothyroidism, affect an estimated 5% of the global population, with higher prevalence in women over 60[^1]. The conventional treatment, levothyroxine (L-T4), has remained relatively unchanged for decades, despite limitations related to absorption variability, dose adjustments, and patient quality of life[^2].

Emerging therapies focus on addressing these limitations, often emphasizing personalized medicine, optimized delivery, and reduced side effects. The global thyroid disorder therapeutics market was valued at approximately USD 1.3 billion in 2022 and is projected to grow at a CAGR of 4.5% through 2030[^3].

Introduction of THYQUIDITY

THYQUIDITY enters this landscape as a potentially differentiated modality. Early clinical data suggest it offers improved bioavailability, reduced dosing complexity, and minimized adverse effects. These attributes could position THYQUIDITY favorably for market adoption, particularly among patients dissatisfied with existing therapies or those with absorption issues.

Market Dynamics

Demand Drivers

• Increasing prevalence: Rising diagnosis of hypothyroidism drives steady demand.
• Limitations of existing therapies: Variability in response to levothyroxine prompts demand for more predictable options.
• Personalized medicine push: Customization of doses with new agents aligns with trend towards tailored therapies.
• Aging population: Greater disease burden among elderly patients boosts for thyroid therapies in general.
• Patient preferences: Desire for once-daily formulations and fewer side effects enhances attractiveness of innovative agents like THYQUIDITY.

Supply-Side Factors

• Manufacturing complexity: High-quality synthesis and stability requirements influence supply chain management.
• Pricing and reimbursement policies: Navigating reimbursement landscapes significantly impacts market penetration.
• Regulatory pathways: Accelerated approvals or expedited review processes (e.g., via FDA’s Breakthrough Therapy designation) could shorten time-to-market.

Competitive Landscape

• Established players: Novartis, Merck, and Pfizer dominate with long-standing levothyroxine formulations.
• Emerging competitors: Several biotech firms are developing alternative therapies, including liothyronine combinations and novel delivery systems.
• Differentiation strategies: THYQUIDITY’s key value propositions include superior bioavailability, fewer side effects, and ease of use. Competitive advantage hinges on clinical validation and cost-effectiveness.

Regulatory and Pricing Environment

• Regulatory hurdles: Approval from agencies like the FDA, EMA, and respective national authorities requires comprehensive safety and efficacy data.
• Pricing pressures: Payers demand cost-effectiveness, especially amid multiple therapies with similar indications.
• Reimbursement landscape: Success depends on favorable reimbursement codes and formulary placements.

Financial Trajectory

Developmental Phase and Investment Needs

Assuming THYQUIDITY currently is in Phase 3 clinical trials, projected expenditures include clinical operations, regulatory submissions, and commercialization preparations. Historically, late-stage development costs span USD 200-500 million[^4], depending on trial size and complexity.

Market Entry and Revenue Projections

• Initial Launch (Years 1-3): Adoption rates are modest initially, targeting specialty clinics and endocrinologists. Revenue could range from USD 50-150 million annually, contingent on clinical validation, market uptake, and pricing.
• Growth Phase (Years 4-7): As adoption expands, especially in outpatient and primary care settings, revenues could escalate to USD 300-600 million annually.
• Long-Term Outlook (post-7 years): Market saturation, generic competition, and potential line extensions influence sustained revenue. A conservative estimate suggests a peak annual revenue of USD 700 million to USD 1 billion, depending on market penetration and therapeutic positioning.

Profitability and Investment Returns

Assuming manufacturing efficiency and optimized pricing strategies, gross margins could reach 60-70%. Operating margins would depend on commercialization expenses and competitive pressures, estimated around 25-40%. Return on investment (ROI) hinges on market share gained and time-to-scale; early adopters may realize multiple-fold ROI within 8-10 years post-launch.

Risk Factors Impacting Financial Trajectory

• Regulatory delays or denials could defer revenue realization.
• Market resistance from clinicians favoring established therapies.
• Pricing restrictions imposed by payers.
• Competitive innovations potentially undermining THYQUIDITY’s market share.

Summary

THYQUIDITY's success relies on clinical validation, strategic regulatory positioning, and effective commercialization. Its financial path will mirror the broader trends in personalized thyroid therapy, with initial investments giving way to revenue growth as it gains market share. Given current market trends and evolving treatment paradigms, THYQUIDITY exhibits promising potential to carve a significant niche, especially if it successfully addresses unmet needs.

Key Takeaways

• The thyroid disorder therapeutics market presents a stable growth trajectory driven by demographic shifts and unmet clinical needs.
• THYQUIDITY's differentiated profile offers a competitive edge but requires robust clinical data and strategic regulatory navigation.
• Financial prospects depend on successful clinical development, market acceptance, reimbursement policies, and competitive dynamics.
• Early investment in commercialization and payer engagement will be critical for maximizing revenue potential.
• Long-term success hinges on sustaining innovation, managing competitive threats, and adapting to evolving healthcare policies.

FAQs

1. What distinguishes THYQUIDITY from existing thyroid therapies?
   THYQUIDITY offers higher bioavailability, standardized dosing, reduced side effects, and improved patient compliance compared to traditional levothyroxine formulations.

2. What regulatory challenges does THYQUIDITY face?
   The primary challenges include demonstrating safety and efficacy through comprehensive clinical trials, obtaining approvals from agencies like the FDA and EMA, and navigating complex reimbursement landscapes.

3. How does the competitive landscape influence THYQUIDITY’s market prospects?
   Dominance by established players and emerging therapies focused on personalized medicine necessitate strategic positioning, clinical differentiation, and cost-competitive pricing for market penetration.

4. What are the key factors impacting the financial success of THYQUIDITY?
   Factors include successful clinical trial outcomes, regulatory approval speed, payer acceptance, market adoption rates, and competitive pressures.

5. When can investors expect to see revenue from THYQUIDITY?
   Assuming successful late-stage clinical trials and regulatory approval, revenue realization could commence within 3-5 years post-launch, with significant growth anticipated over the subsequent decade.

---

Sources

[^1]: National Institute of Diabetes and Digestive and Kidney Diseases. Thyroid disease. (2022).
[^2]: Jonklaas J, et al. Practice guidelines for hypothyroidism. Thyroid. 2014.
[^3]: Grand View Research. Thyroid Disorder Therapeutics Market Size & Trends. 2022.
[^4]: DiMasi JA, et al. Innovation in industry and government. Pharmacoeconomics. 2018.